Charles River LaboratoriesCRLEarnings & Financial Report
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.
CRL Q1 FY2026 Key Financial Metrics
Revenue
$995.8M
Gross Profit
N/A
Operating Profit
$119.9M
Net Profit
$-14.8M
Gross Margin
N/A
Operating Margin
12.0%
Net Margin
-1.5%
YoY Growth
1.2%
EPS
$-0.30
Charles River Laboratories Q1 FY2026 Financial Summary
Charles River Laboratories reported revenue of $995.8M (up 1.2% YoY) for Q1 FY2026, with a net profit of $-14.8M (down 157.2% YoY) (-1.5% margin).
Key Financial Metrics
| Total Revenue | $995.8M |
|---|---|
| Net Profit | $-14.8M |
| Gross Margin | N/A |
| Operating Margin | 12.0% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Charles River Laboratories Q1 FY2026 revenue of $995.8M breaks down across 2 segments, led by Service revenue at $798.2M (80.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Service revenue | $798.2M | 80.1% |
| Product revenue | $197.7M | 19.9% |
Charles River Laboratories Annual Revenue by Year
Charles River Laboratories annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.0B).
Charles River Laboratories Quarterly Revenue & Net Profit History
Charles River Laboratories results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $995.8M | +1.2% | $-14.8M | -1.5% |
| Q4 FY2025 | $994.2M | -0.8% | $-276.6M | -27.8% |
| Q3 FY2025 | $1.0B | -0.5% | $54.4M | 5.4% |
| Q2 FY2025 | $1.0B | +0.6% | $52.3M | 5.1% |
| Q1 FY2025 | $984.2M | -2.7% | $25.5M | 2.6% |
| Q4 FY2024 | $1.0B | -1.1% | $-214.5M | -21.4% |
| Q3 FY2024 | $1.0B | -1.6% | $69.7M | 6.9% |
| Q2 FY2024 | $1.0B | -0.3% | $94.1M | 9.2% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.03B | $1.01B | $1.00B | $984.2M | $1.03B | $1.00B | $994.2M | $995.8M |
| YoY Growth | -0.3% | -1.6% | -1.1% | -2.7% | 0.6% | -0.5% | -0.8% | 1.2% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.95B | $8.00B | $7.53B | $7.58B | $7.56B | $7.51B | $7.14B | $7.73B |
| Liabilities | $4.18B | $4.18B | $4.02B | $4.34B | $4.16B | $4.06B | $3.92B | $4.74B |
| Equity | $3.72B | $3.78B | $3.46B | $3.19B | $3.35B | $3.41B | $3.16B | $2.95B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $193.5M | $251.8M | $159.4M | $171.7M | $204.6M | $213.8M | $147.5M | $41.1M |